Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Rania Hamed. (2018) Physiological parameters of the gastrointestinal fluid impact the dissolution behavior of the BCS class IIa drug valsartan. Pharmaceutical Development and Technology 23:10, pages 1168-1176.
Read now
Read now
Mahesh Attimarad, Sree Harsha Nagaraja, Anroop Balachandran Nair, Bandar Essa Aldhubaib & Venugopala Narayanaswamy Katharigatta. (2018) Development of validated RP HPLC method with fluorescence detection for simultaneous quantification of sacubitril and valsartan from rat plasma. Journal of Liquid Chromatography & Related Technologies 41:5, pages 246-252.
Read now
Read now
Massimo Volpe. (2012) Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan. Expert Review of Cardiovascular Therapy 10:8, pages 1061-1072.
Read now
Read now
Rossana Baracco & Gaurav Kapur. (2011) Clinical utility of valsartan in the treatment of hypertension in children and adolescents. Patient Preference and Adherence 5, pages 149-155.
Read now
Read now
Christian Höcht, Facundo Martín Bertera, Marcos Alejandro Mayer & Carlos Alberto Taira. (2010) Issues in drug metabolism of major antihypertensive drugs: β-blockers, calcium channel antagonists and angiotensin receptor blockers. Expert Opinion on Drug Metabolism & Toxicology 6:2, pages 199-211.
Read now
Read now
Naylin Bissessor & Harvey White. (2007) Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction. Vascular Health and Risk Management 3:4, pages 425-430.
Read now
Read now
Bodh I Jugdutt. (2006) Valsartan in the Treatment of Heart Attack Survivors. Vascular Health and Risk Management 2:2, pages 125-138.
Read now
Read now
Tarik M. Ramahi. (2001) Expanded role for ARBs in cardiovascular and renal disease?. Postgraduate Medicine 109:4, pages 115-122.
Read now
Read now
Articles from other publishers (15)
NS YamaniMukthinuthalapati Mathrusri Annapurna. (2023) New stability indicating liquid chromatographic method for the estimation of Valsartan in pharmaceutical dosage forms. Research Journal of Pharmacy and Technology, pages 1484-1490.
Crossref
Crossref
Rania Hamed & Areej Kamal. (2021) Strength-Dependent and Strength-Independent Dissolution Patterns of Poorly-Soluble Drugs. Case Example: Valsartan. Pharmaceutical Chemistry Journal 54:12, pages 1227-1234.
Crossref
Crossref
Valeria R. Martínez, María V. Aguirre, Juan S. Todaro, Evelina G. Ferrer & Patricia A. M. Williams. (2021)
Candesartan and valsartan Zn(
ii
) complexes as inducing agents of reductive stress: mitochondrial dysfunction and apoptosis
. New Journal of Chemistry 45:2, pages 939-951.
Crossref
Crossref
Tran Van Chien, Nguyen The Anh, Tran Thi Phuong Thao, Le Dac Phuong, Pham Thi Tham, Nguyen Quang Tung & Tran Van Loc. (2019) Synthesis of Valsartan as drug for the treatment of hypertension. Vietnam Journal of Chemistry 57:3, pages 343-346.
Crossref
Crossref
Raja Haranadha Babu Chunduri & Gowri Sankar Dannana. (2016) Development and validation of a reliable and rapid LC-MS/MS method for simultaneous quantification of sacubitril and valsartan in rat plasma and its application to a pharmacokinetic study. Biomedical Chromatography 30:9, pages 1467-1475.
Crossref
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs
329
356
.
Yanzhuo Zhang, Erxi Che, Miao Zhang, Baoxiang Sun, Jian Gao, Jin Han & Yaling Song. (2014) Increasing the dissolution rate and oral bioavailability of the poorly water-soluble drug valsartan using novel hierarchical porous carbon monoliths. International Journal of Pharmaceutics 473:1-2, pages 375-383.
Crossref
Crossref
Sarwar Beg, Suryakanta Swain, Harendra Pratap Singh, Ch Niranjan Patra & ME Bhanoji Rao. (2012) Development, Optimization, and Characterization of Solid Self-Nanoemulsifying Drug Delivery Systems of Valsartan Using Porous Carriers. AAPS PharmSciTech 13:4, pages 1416-1427.
Crossref
Crossref
Thomas Unger. (2012) Preclinical and Clinical Effects of RAS Inhibition with a Focus on Telmisartan. ISRN Vascular Medicine 2012, pages 1-11.
Crossref
Crossref
C. Potamitis, P. Chatzigeorgiou, E. Siapi, K. Viras, T. Mavromoustakos, A. Hodzic, G. Pabst, F. Cacho-Nerin, P. Laggner & M. Rappolt. (2011) Interactions of the AT1 antagonist valsartan with dipalmitoyl-phosphatidylcholine bilayers. Biochimica et Biophysica Acta (BBA) - Biomembranes 1808:6, pages 1753-1763.
Crossref
Crossref
Constantinos PotamitisMaria ZervouVassilis KatsiarasPanagiotis ZoumpoulakisSerdar DurdagiManthos G. PapadopoulosJoseph M. HayesSimona Golic GrdadolnikIoanna KyrikouDimitris ArgyropoulosGeorgia VatougiaThomas Mavromoustakos. (2009)
Antihypertensive Drug Valsartan in Solution and at the AT
1
Receptor: Conformational Analysis, Dynamic NMR Spectroscopy,
in Silico
Docking, and Molecular Dynamics Simulations
. Journal of Chemical Information and Modeling 49:3, pages 726-739.
Crossref
Crossref
Thomas Unger & Bernward A. SchölkensM. Maillard & M. Burnier. 2004. Angiotensin Vol. II. Angiotensin Vol. II
453
484
.
Marion Gurrath. (2001) Der humane AT1-Rezeptor: Wettlauf um ein neues Target. Pharmazie in unserer Zeit 30:4, pages 288-295.
Crossref
Crossref
M. P. Maillard, J. Rossat, J. Nussberger, J. Ramis, C. Pontes, M. Burnier & H. R. Brunner. (2000) Pharmacologic Profile of UR-7247, an Orally Active Angiotensin II AT1 Receptor Antagonist, in Healthy Volunteers. Journal of Cardiovascular Pharmacology 35:3, pages 383-389.
Crossref
Crossref
M Burnier & HR Brunner. (2000) Angiotensin II receptor antagonists. The Lancet 355:9204, pages 637-645.
Crossref
Crossref